Showing results (111-120 of 154) with videos related to

Sort By:
Pageof 16
Journal of the European Academy of Dermatology and Venereology : JEADV|June 19, 2023
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND studyKristian Reich, Jonathan I Silverberg, Kim A Papp, et al.
American Journal of Clinical Dermatology|May 9, 2019
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled AnalysisLawrence F Eichenfield, Thomas Bieber, Lisa A Beck, et al.
Eclinicalmedicine|January 27, 2025
Roads to remission: evolving treatment concepts in type 2 inflammatory diseasesMarek Lommatzsch, Katharina Blumchen, Lisa A Beck, et al.
The Journal of Allergy and Clinical Immunology|September 8, 2015
Targeted deep sequencing identifies rare loss-of-function variants in IFNGR1 for risk of atopic dermatitis complicated by eczema herpeticumLi Gao, Lianghua Bin, Nicholas M Rafaels, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 14, 2023
Phenotypic and Endotypic Determinants of Atopic Dermatitis Severity From the Atopic Dermatitis Research Network (ADRN) RegistryEric L Simpson, Anna De Benedetto, Mark Boguniewicz, et al.
The Journal of Allergy and Clinical Immunology|September 29, 2024
CERS1 is a biomarker of Staphylococcus aureus abundance and atopic dermatitis severityH Mark Kenney, Takeshi Yoshida, Evgeny Berdyshev, et al.
The New England Journal of Medicine|July 10, 2014
Dupilumab treatment in adults with moderate-to-severe atopic dermatitisLisa A Beck, Diamant Thaçi, Jennifer D Hamilton, et al.
Pageof 16